Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Treasury Shares: 2017-2025

Historic Treasury Shares for Cidara Therapeutics (CDTX) over the last 8 years, with Sep 2025 value amounting to $367,004.

  • Cidara Therapeutics' Treasury Shares rose 86.16% to $367,004 in Q3 2025 from the same period last year, while for Sep 2025 it was $367,004, marking a year-over-year increase of 86.16%. This contributed to the annual value of $177,273 for FY2024, which is 69.01% up from last year.
  • According to the latest figures from Q3 2025, Cidara Therapeutics' Treasury Shares is $367,004, which was down 7.28% from $395,835 recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Treasury Shares registered a high of $2.3 million during Q1 2023, and its lowest value of $104,886 during Q4 2023.
  • For the 3-year period, Cidara Therapeutics' Treasury Shares averaged around $767,575, with its median value being $337,754 (2025).
  • Its Treasury Shares has fluctuated over the past 5 years, first spiked by 308.35% in 2022, then slumped by 94.65% in 2024.
  • Over the past 5 years, Cidara Therapeutics' Treasury Shares (Quarterly) stood at $1.2 million in 2021, then grew by 4.24% to $1.2 million in 2022, then tumbled by 91.43% to $104,886 in 2023, then soared by 69.01% to $177,273 in 2024, then spiked by 86.16% to $367,004 in 2025.
  • Its Treasury Shares stands at $367,004 for Q3 2025, versus $395,835 for Q2 2025 and $337,754 for Q1 2025.